Tango Therapeutics Inc. (TNGX)
Stock · NASDAQ · Health Care
$22.05as of 10/16/2026
Price chart
Active signals
TNGX Signal Track Record
How signals performed across all stocks →What TNGX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -0.9% | 49% | September 23, 2026 |
| Bollinger Band Breakdown | 25 | +7.1% | 56% | August 20, 2026 |
| Bollinger Band Breakout | 21 | +7.6% | 62% | June 8, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +9.0% | 75% | August 6, 2024 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 137
- Website
- www.tangotx.com/
Fundamentals
- 1-day range
- $21.82$23.17
- Market cap
- $4.19B
- P/E (trailing)
- —
- P/E (forward)
- -13.27
- EPS (trailing)
- $-0.84
- Dividend yield
- —
- Beta
- 1.18
- Avg. volume
- 2.78M
How Tango Therapeutics Inc. Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Tango Therapeutics Inc. Competitors
Chosen by industry and closest market cap.
- TNGXTango Therapeutics Inc.$22.04▼ 2.91%Market cap $4.19BP/E —$6.69$34.39
- PBLSParabilis Medicines Inc. Common Stock$22.75▼ 9.65%Market cap $4.23BP/E —$24.51$42.49
- VKTXViking Therapeutics Inc. Common Stock$25.17▼ 8.04%Market cap $3.88BP/E —$25.77$43.15
- MANEVeradermics Incorporated Common Stock$108.82▼ 5.43%Market cap $4.54BP/E —$32$136.72
- GMABGenmab A/S ADS$37▼ 2.17%Market cap $3.83BP/E 26.41$1,512$2,369
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TNGX Tango Therapeutics Inc. | $4.19B | — | $22.04 | ▼ 2.91% | $6.69$34.39 |
| PBLS Parabilis Medicines Inc. Common Stock | $4.23B | — | $22.75 | ▼ 9.65% | $24.51$42.49 |
| VKTX Viking Therapeutics Inc. Common Stock | $3.88B | — | $25.17 | ▼ 8.04% | $25.77$43.15 |
| MANE Veradermics Incorporated Common Stock | $4.54B | — | $108.82 | ▼ 5.43% | $32$136.72 |
| GMAB Genmab A/S ADS | $3.83B | 26.41 | $37 | ▼ 2.17% | $1,512$2,369 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Tango Therapeutics with Outperform Ratingbenzinga · 10/16/2026
Insider Activity
Insider Actions →- Crystal Adam · October 1, 2026 · Option Exercise27.0K @ $5.2
- Crystal Adam · October 1, 2026 · Sale600 @ $25.32
- Crystal Adam · October 1, 2026 · Sale26.4K @ $24.45
- Newcomb Jessica · September 22, 2026 · Sale2.4K @ $25.17
- Newcomb Jessica · September 22, 2026 · Sale5.1K @ $23.97
- Newcomb Jessica · September 22, 2026 · Sale700 @ $22.8
- Crystal Adam · September 1, 2026 · Option Exercise27.0K @ $5.2
- Crystal Adam · September 1, 2026 · Sale27.0K @ $22.37
- Crystal Adam · August 3, 2026 · Option Exercise27.0K @ $5.2
- Crystal Adam · August 3, 2026 · Sale21.7K @ $27.35
- Crystal Adam · August 3, 2026 · Sale5.3K @ $26.79
- Crystal Adam · July 1, 2026 · Option Exercise27.0K @ $5.2
- Crystal Adam · July 1, 2026 · Sale7.4K @ $30.25
- Crystal Adam · July 1, 2026 · Sale19.6K @ $29.34
- Robert Azelby · June 19, 2026 · Grant5.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 178.71M
- Total value held
- $3.69B
- Institutional holders
- 189
- Unknown13.30M
- Unknown12.81M
- Unknown10.88M
- Unknown10.53M
- Unknown9.91M
- Unknown9.10M
- Unknown8.75M
- Unknown8.00M
- Unknown7.27M
- Unknown6.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.